Subscribe
-
At CanSinoBIO, our main research and development focus is vaccinesIn the future, we plan to promote the development and commercialization of near commercialized vaccine products; promote the development of other vaccine product lines under research; establish and consolidate our commercialized infrastructure -
CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in ChinaCanSinoBIO announced today that its Recombinant Novel Coronavirus Vaccine candidate, co-developed with Beijing Institute of Biotechnology (BIB), has been approved to enter into Phase 1 Clinical Trial.
Research and products
At CanSinoBIO, our main research and development focus is vaccines.
Areas Of Focus
We apply our expertise across a range targets from antigen discovery, antigen overexpression, purification and formulation to proof-of-concept pre-clinical evaluation, production process development and assay development.
Pipeline
We have an impressive array of vaccine candidates currently undergoing pre-clinical studies including recombinant protein-based pneumococcal vaccines, adenovirus-based recombinant TB vaccines, and polyvalent conjugate vaccines.
Technology Platform
Our team works with world’s most advanced equipment and lab resources for microbiology, molecular cell biology, immunology and biochemistry. We also maintain top- notch animal research facilities.
Investors
We apply our expertise across a range targets from antigen discovery, antigen overexpression,
purification and formulation to proof-of-concept pre-clinical evaluation,
production process development and assay development.
purification and formulation to proof-of-concept pre-clinical evaluation,
production process development and assay development.
Information disclosure
Stock information
Corporate governance
Calendar
-
13/082020SHANGHAI, CHINA, August 13, 2020, CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX:06185) announced today that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+ H" dual listing vaccine company. CanSinoBIO will issue 24.8 million shares at the issue price of RMB209.71 per Share.
-
17/032020TIANJIN, CHINA, March 17, 2020, CanSino Biologics Inc. (“CanSinoBIO”, HK6185), an innovative biopharmaceutical company dedicated to vaccine R&D and commercialization, announced today that its Recombinant Novel Coronavirus Vaccine ...
-
02/012020TIANJIN, CHINA, January 2, 2020, CanSino Biologics Inc. (“CanSinoBIO” or the “Company”, 6185.HK) announced the appointment of Dr. Pierre Armand Morgon as Senior Vice President responsible for international business operation. The appointment indicated a further step forward in the Company’s commitment to global development and growth.
-
16/122019TIANJIN, CHINA, December 16, 2019, CanSino Biologics Inc. (“CanSinoBIO”, HK6185) announced today that the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has granted Priority Review designation to the Company’s NDA for its investigational quadrivalent meningococcal (serogroups A, C, W-135 and Y) conjugate vaccine (MenhyciaTM), according to the latest CDE announcement on its website.
-
26/112019TIANJIN, CHINA, November 26th, 2019, CanSino Biologics Inc. (“CanSinoBIO”, HK6185) signed a Memorandum on Reciprocal Developmental Programs with Tianjin Medical Products Administration (TMPA), in an effort to strengthen the regulator’s capacity and capabilities on routine surveillance inspections to vaccine manufacturers.
